Research programme: spinal cord injury cell therapy - NosciraAlternative Names: GOE; OEG
Latest Information Update: 07 Mar 2013
At a glance
- Originator Noscira
- Class Cell therapies
- Mechanism of Action Tissue replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Spinal cord injuries